OTCPK:CVSI

Stock Analysis Report

Executive Summary

CV Sciences, Inc. operates as a life science company.

Snowflake

Fundamentals

High growth potential with excellent balance sheet.

Risks

  • CV Sciences has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has CV Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.2%

OTCPK:CVSI

-3.2%

US Personal Products

-1.0%

US Market


1 Year Return

-51.7%

OTCPK:CVSI

8.1%

US Personal Products

-0.4%

US Market

CVSI underperformed the Personal Products industry which returned 8.1% over the past year.

CVSI underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

CVSIIndustryMarket
7 Day2.2%-3.2%-1.0%
30 Day-22.6%-6.3%-3.3%
90 Day-31.5%-1.3%0.8%
1 Year-51.7%-51.7%9.7%8.1%1.9%-0.4%
3 Year1099.7%1099.7%25.7%19.2%39.4%30.4%
5 Year-3.3%-3.3%62.8%46.4%54.2%37.1%

Price Volatility Vs. Market

How volatile is CV Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CV Sciences undervalued based on future cash flows and its price relative to the stock market?

9.18x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

CV Sciences's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

CV Sciences's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

CV Sciences is loss making, we can't compare its value to the US Personal Products industry average.

CV Sciences is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for CV Sciences, we can't assess if its growth is good value.


Price Based on Value of Assets

CV Sciences is overvalued based on assets compared to the US Personal Products industry average.


Next Steps

Future Growth

How is CV Sciences expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

119.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

CV Sciences's revenue is expected to grow significantly at over 20% yearly.

CV Sciences's earnings are expected to grow significantly at over 20% yearly.

CV Sciences's revenue growth is expected to exceed the United States of America market average.

CV Sciences's earnings growth is expected to exceed the United States of America market average.

CV Sciences's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if CV Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has CV Sciences performed over the past 5 years?

14.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

CV Sciences does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare CV Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare CV Sciences's 1-year growth to the US Personal Products industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if CV Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if CV Sciences has efficiently used its assets last year compared to the US Personal Products industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if CV Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is CV Sciences's financial position?


Financial Position Analysis

CV Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

CV Sciences's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

CV Sciences's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).

Unable to establish if CV Sciences's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 547.8x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making CV Sciences has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making CV Sciences has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -104.5% per year.


Next Steps

Dividend

What is CV Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate CV Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate CV Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as CV Sciences has not reported any payouts.

Unable to verify if CV Sciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as CV Sciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of CV Sciences's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Joe Dowling (62yo)

1.3yrs

Tenure

US$733,959

Compensation

Mr. Joseph D. Dowling, also known as Joe, has been its Chief Executive Officer at CV Sciences, Inc. since May 31, 2018 and Secretary since August 25, 2014. Mr. Dowling served as Chief Financial Officer at  ...


CEO Compensation Analysis

Joe's remuneration is lower than average for companies of similar size in United States of America.

Joe's compensation has increased whilst company is loss making.


Management Age and Tenure

0.8yrs

Average Tenure

62yo

Average Age

The average tenure for the CV Sciences management team is less than 2 years, this suggests a new team.


Board Age and Tenure

2.3yrs

Average Tenure

65.5yo

Average Age

The average tenure for the CV Sciences board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Joe Dowling (62yo)

    CEO, Secretary & Director

    • Tenure: 1.3yrs
    • Compensation: $733.96k
  • Duffy MacKay

    Senior VP of Scientific & Regulatory Affairs

    • Tenure: 0.4yrs
  • Michael Mona (33yo)

    Co-Founder

    • Compensation: $681.75k
  • Joseph Maroon (78yo)

    MD & Director

    • Tenure: 1.6yrs
    • Compensation: $1.00m
  • Joerg Grasser

    Chief Financial Officer

    • Tenure: 0.4yrs
    • Compensation: $816.51k

Board Members

  • Alexandros Makriyannis

    Member of Advisory Board

  • Jim McNulty (69yo)

    Independent Director

    • Tenure: 3.6yrs
    • Compensation: $131.84k
  • Michael Mona (33yo)

    Co-Founder

    • Tenure: 3.3yrs
    • Compensation: $681.75k
  • Michael Lewis

    Member of Advisory Board

  • Joseph Maroon (78yo)

    MD & Director

    • Tenure: 1.0yrs
    • Compensation: $1.00m
  • Tim Ziegenfuss

    Member of Advisory Board

  • Aimee Shunney

    Member of Advisory Board

  • Joe Dowling (62yo)

    CEO, Secretary & Director

    • Tenure: 1.3yrs
    • Compensation: $733.96k
  • John Hicks

    Member of Advisory Board

  • Jeff Anshel

    Member of Advisory Board

Company Information

CV Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CV Sciences, Inc.
  • Ticker: CVSI
  • Exchange: OTCPK
  • Founded: 2010
  • Industry: personal products
  • Sector: household
  • Market Cap: US$316.555m
  • Shares outstanding: 99.23m
  • Website: Click here

Number of Employees


Location

  • CV Sciences, Inc.
  • 10070 Barnes Canyon Road
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CVSIOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2011

Biography

CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consu ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 00:34
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.